Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 14,922 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disorders Clear all
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

NCT02301936
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 19, 2026, 4:07 PM EDT
Terminated Phase 4 Interventional Results available

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

NCT02308111
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
43
States / cities
Phoenix, Arizona • Los Angeles, California • Rialto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 19, 2026, 4:07 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

NCT01871571
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 4:07 PM EDT
Completed Phase 1 Interventional

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

NCT00604409
View directory record Official record
Conditions
Metastatic Liver Cancer
Interventions
SIRT, capecitabine
Radiation · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 19, 2026, 4:07 PM EDT
Completed No phase listed Observational

Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)

NCT02363309
View directory record Official record
Conditions
Fatty Liver
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 19, 2026, 4:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Gemcabene in Adults With FPLD

NCT03508687
View directory record Official record
Conditions
Familial Partial Lipodystrophy, Hypertriglyceridemia, Fatty Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
300mg Gemcabene, 600mg Gemcabene
Drug
Lead sponsor
Elif Oral
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 19, 2026, 4:07 PM EDT
Active, not recruiting Not applicable Interventional

A Culturally Tailored Dietary Intervention to Treat Crohn's Disease

NCT05627128
View directory record Official record
Conditions
Crohn Disease
Interventions
DAIN
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 19, 2026, 4:07 PM EDT
Terminated Phase 3 Interventional Results available

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

NCT00372567
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
sunitinib malate, imatinib mesylate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Detroit, Michigan • Farmington Hills, Michigan • City of Saint Peters, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Oct 19, 2026, 4:07 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

NCT01966367
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
Interventions
CD34 Stem Cell Selection Therapy
Biological
Lead sponsor
Diane George
Other
Eligibility
Up to 40 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 19, 2026, 4:07 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome

NCT01906307
View directory record Official record
Conditions
Hepatorenal Syndrome Type I and Type II
Interventions
LJPC-501
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 19, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

NCT00783692
View directory record Official record
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
110
States / cities
Birmingham, Alabama • Los Angeles, California • Montebello, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 19, 2026, 4:07 PM EDT
Completed No phase listed Observational

Genomics of Primary Sclerosing Cholangitis (PSC)

NCT01161992
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Genetic Analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
5 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 19, 2026, 4:07 PM EDT
Terminated Phase 1 Interventional Results available

A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer

NCT00779311
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
sorafenib, bevacizumab, mFOLFOX6 regimen
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Macon, Georgia • Billings, Montana • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 19, 2026, 4:07 PM EDT
Completed Not applicable Interventional

Internet-based Pain Self-management for Persons With Acute Recurrent and Chronic Pancreatitis Pain

NCT03322644
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatitis, Acute Recurrent
Interventions
Internet-based CBT intervention
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 19, 2026, 4:07 PM EDT
Not listed Phase 2 Interventional

Chemotherapy in Treating Patients With Liver Cancer

NCT00003044
View directory record Official record
Conditions
Liver Cancer
Interventions
cisplatin-e therapeutic implant
Drug
Lead sponsor
Matrix Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
2
States / cities
Baltimore, Maryland • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 19, 2026, 4:07 PM EDT
Withdrawn Not applicable Interventional

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

NCT02700087
View directory record Official record
Conditions
Laryngomalacia, Acid Reflux, Stridor
Interventions
ranitidine or famotidine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 4 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 19, 2026, 4:07 PM EDT
Terminated Not applicable Interventional

Routine Post-Operative Supplemental Nutrition

NCT02297607
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Tube Feeding
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 19, 2026, 4:07 PM EDT
Completed Not applicable Interventional Results available

Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies

NCT01401907
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Esophageal Cancer, Gastric Cancer, Liver Cancer, Pancreatic Cancer
Interventions
early palliative care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 19, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA

NCT00334607
View directory record Official record
Conditions
Infections, Rotavirus
Interventions
2-dose oral live attenuated G1P[8] human rotavirus vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 16 Weeks
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
42
States / cities
Benton, Arkansas • Cabot, Arkansas • Jonesboro, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 19, 2026, 4:07 PM EDT
Terminated Phase 2 Interventional Results available

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

NCT01391611
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
Pazopanib
Drug
Lead sponsor
Kristen Ganjoo
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 19, 2026, 4:07 PM EDT
Active, not recruiting Phase 1 Interventional

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

NCT01660971
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Dasatinib, Erlotinib Hydrochloride, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 4:07 PM EDT
Completed Phase 2 Interventional

SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

NCT00110799
View directory record Official record
Conditions
Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
Interventions
SB497115, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 19, 2026, 4:07 PM EDT
Withdrawn Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer

NCT00025532
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
iodine I 131 monoclonal antibody CC49-deltaCH2
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 19, 2026, 4:07 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease

NCT01442363
View directory record Official record
Conditions
Perianal Crohn's Disease
Interventions
BLI-1300 low dose, BLI-1300 high dose, placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
17
States / cities
Anaheim, California • San Francisco, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 19, 2026, 4:07 PM EDT